Sarepta Therapeutics Inc (NASDAQ:SRPT) Receives $187.06 Average PT from Analysts
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have been given a consensus recommendation of “Buy” by the twenty-four analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $187.06.
A number of brokerages have issued reports on SRPT. Royal Bank of Canada set a $204.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 24th. Bank of America cut their target price on shares of Sarepta Therapeutics from $200.00 to $189.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Credit Suisse Group cut their target price on shares of Sarepta Therapeutics from $201.00 to $185.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. HC Wainwright set a $160.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Friday, September 13th. Finally, Morgan Stanley cut their target price on shares of Sarepta Therapeutics from $220.00 to $160.00 and set an “overweight” rating on the stock in a report on Friday, October 11th.
In other news, Director Richard Barry bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average price of $87.49 per share, with a total value of $437,450.00. Following the completion of the acquisition, the director now directly owns 3,183,756 shares in the company, valued at $278,546,812.44. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David T. Howton sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $105.00, for a total value of $2,625,000.00. Following the sale, the executive vice president now directly owns 24,388 shares in the company, valued at approximately $2,560,740. The disclosure for this sale can be found here. 6.60% of the stock is owned by insiders.
NASDAQ:SRPT traded up $1.11 during mid-day trading on Monday, reaching $102.56. The stock had a trading volume of 6,144 shares, compared to its average volume of 1,211,820. The company has a market capitalization of $7.88 billion, a price-to-earnings ratio of -18.78 and a beta of 2.30. Sarepta Therapeutics has a 1-year low of $72.05 and a 1-year high of $158.80. The stock’s 50 day simple moving average is $98.96 and its two-hundred day simple moving average is $111.06. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.31 and a quick ratio of 5.54.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.35). The firm had revenue of $99.04 million during the quarter, compared to analyst estimates of $98.49 million. Sarepta Therapeutics had a negative return on equity of 55.44% and a negative net margin of 169.87%. The firm’s revenue for the quarter was up 26.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.15) earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post -6.02 EPS for the current fiscal year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
See Also: How to Invest in Marijuana Stocks
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.